Physician

Adam Solliday, APRN-CNP

According to 2025 Medicare claims, Adam Solliday, APRN-CNP (NPI: 1992349815) practices nurse practitioner in the Springfield, OH market, with the plurality of this provider's patient population coming from Clark, OH. This provider's primary affiliated billing organization is OSU INTERNAL MEDICINE, LLC (NPI: 1740231448; TIN: 311369596) and primary practice location at 43210-1240. Solliday is affiliated with the CVS ACO (ACO ID: A5407), participating under the MSSP model.

Solliday's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 22 traditional Medicare patients, billed 24 HCPCS/CPT codes, and received $652 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 449 prescription claims across 140 beneficiaries totaling $202,657 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 2,079 claims. Open Payments data shows 1 records totaling $22. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $10,365 to $652. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, reported payments moved sharply higher in recent years, from $31,059 to $98,853.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	162	207	$10,365
2021	114	139	$8,972
2022	177	227	$13,284
2023	203	355	$19,923
2024	22	24	$652

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	205	620	$195,903
2021	307	1,113	$373,777
2022	473	2,194	$885,156
2023	337	1,430	$617,283
2024	140	449	$202,657

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	345	670	$24,300
2021	425	1,082	$35,915
2022	725	1,696	$64,471
2023	1,037	2,322	$98,928
2024	914	2,079	$108,230

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	14	14	$16

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	85	3,870	$81,158
Breo Ellipta	Fluticasone/Vilanterol	46	1,980	$25,593
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	30	960	$19,878
Incruse Ellipta	Umeclidinium Bromide	25	1,470	$16,623
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	16	780	$11,669

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	17	$12,936
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	12	$12,253
A7032	Cushion for use on nasal mask interface, replacement only, each	N	59	128	$11,496
A7031	Face mask interface, replacement for full face mask, each	N	56	124	$10,913
A7030	Full face mask used with positive airway pressure device, each	N	59	134	$10,662

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$22	Boehringer Ingelheim Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Solliday, APRN-CNP?

Tedicare shows public-source Medicare data for Adam Solliday, APRN-CNP (NPI 1992349815), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Solliday, APRN-CNP have ACO affiliation data?

Adam Solliday, APRN-CNP is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407).

What billing organization is linked to Adam Solliday, APRN-CNP?

Adam Solliday, APRN-CNP is linked to OSU INTERNAL MEDICINE, LLC (billing NPI 1740231448) in the available physician profile data.

Does Adam Solliday, APRN-CNP have Open Payments data?

Adam Solliday, APRN-CNP has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.